MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-16-2026
Novan Total Shareholders Equity 2011-2026 | NOVN
Annual Total Shareholders Equity Novan
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.6 M | 18.3 M | 2.98 M | -22.3 M | 6.44 M | -1.72 M | 31.1 M | -60.1 M | -29.5 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 31.1 M | -60.1 M | -5.58 M |
Quarterly Total Shareholders Equity Novan
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.83 M | 4.6 M | 6.76 M | 12.2 M | 5.88 M | 18.3 M | 26.2 M | 32.3 M | 850 K | 2.98 M | 7.45 M | -37 K | -12.4 M | -22.3 M | -27.6 M | -20.2 M | -2.36 M | 6.44 M | -2.3 M | 4.35 M | 11.4 M | -1.72 M | 5.2 M | 11.7 M | 20.7 M | 31.1 M | 43.4 M | 31.1 M | 31.1 M | -60.1 M | -60.1 M | - | - | -29.5 M | - | - | - | -18.4 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 43.4 M | -60.1 M | 1.64 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
5.1 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
24.3 M | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K |  USA |
 |
Coherus BioSciences
CHRS
|
61 M | $ 1.73 | 5.18 % | $ 203 M | USA |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M | China |
 |
Celldex Therapeutics
CLDX
|
527 M | $ 31.65 | 2.59 % | $ 2.1 B | USA |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B | France |
 |
BioNTech SE
BNTX
|
19.2 B | $ 94.81 | 2.78 % | $ 22.9 B | Germany |
 |
AstraZeneca PLC
AZN
|
48.7 B | - | - | $ 96.9 B |  Britain |
 |
CRISPR Therapeutics AG
CRSP
|
1.92 B | $ 53.52 | 3.74 % | $ 4.81 B |  Schweiz |
 |
Athira Pharma
ATHA
|
27.8 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-14.6 M | - | 0.74 % | $ 768 M |  Israel |
 |
Compugen Ltd.
CGEN
|
103 M | $ 2.68 | 1.13 % | $ 250 M | Israel |
 |
Abcam plc
ABCM
|
727 M | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
3.97 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
11.4 M | - | -18.52 % | $ 27.3 M | Britain |
|
Enlivex Therapeutics Ltd.
ENLV
|
1.93 B | $ 0.78 | 14.04 % | $ 35.6 M | Israel |
 |
Esperion Therapeutics
ESPR
|
-302 M | $ 3.13 | 0.32 % | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
26.2 M | $ 31.66 | 1.18 % | $ 852 M | USA |
 |
Affimed N.V.
AFMD
|
57.8 M | - | -34.95 % | $ 21.5 M | Germany |
|
Forte Biosciences
FBRX
|
61 M | $ 22.13 | 0.87 % | $ 287 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
69.5 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
4.32 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
142 M | - | -7.31 % | $ 87 M | USA |
 |
Galectin Therapeutics
GALT
|
-128 M | $ 2.72 | -2.69 % | $ 174 M | USA |
 |
Generation Bio Co.
GBIO
|
86.2 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
-6.6 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | Israel |
 |
Grifols, S.A.
GRFS
|
8.61 B | $ 8.08 | 0.9 % | $ 5.49 B |  Spain |
 |
Hutchison China MediTech Limited
HCM
|
1.24 B | $ 11.72 | -0.26 % | $ 10.1 B | China |
 |
Cyclacel Pharmaceuticals
CYCCP
|
6.84 M | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
52.4 M | - | - | $ 384 M | Britain |
 |
Heron Therapeutics
HRTX
|
14.3 M | $ 0.9 | 2.13 % | $ 150 M | USA |
 |
Gracell Biotechnologies
GRCL
|
1.38 B | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
143 M | $ 14.76 | -0.87 % | $ 212 M | USA |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
 |
InflaRx N.V.
IFRX
|
41.6 M | $ 2.6 | -5.11 % | $ 175 M | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.59 M | $ 3.35 | -4.83 % | $ 5.51 M | Israel |